(833) 317-6278
Book a Demo
Matthew Herper
Gray shield icon
Is this you?
Claim your profile.

Matthew Herper

Senior Writer, Medicine, and Editorial Director, Events

AS SEEN ON
STAT, everand.com

Preston's Summary

Matthew Herper is a Senior Writer for STAT and the Editorial Director of Events. With a focus on medicine and biology, he covers a wide range of topics including the latest developments in healthcare, scientific breakthroughs, and the pharmaceutical industry. Matthew's work provides in-depth analysis and reporting on complex medical issues, making it accessible to a broad audience.

Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston

Geo Focus

United States (National)

Coverage Attributes:

Beta
Press Release: 25 %
Cites Data: 21 %
Private Sector Announcements: 13 %
Investment Analysis: 9 %
Government Announcement: 7 %

Themes Covered:

Not enough data icon

Not enough data

Most Recent Topics:

  • Oncology
  • Patient Care
  • Public Health
  • Immunotherapy

Pitching Insights

Matthew Herper's coverage primarily focuses on the healthcare and pharmaceutical sectors, with an emphasis on data-driven insights and industry announcements. His articles frequently cite data, incorporate press releases, and feature private sector announcements.

Given his extensive use of data in reporting, he may be particularly interested in sources who can provide statistical analysis or empirical evidence related to developments in pharmaceuticals, medical research, cancer treatment, gene editing, or drug development.

He does not appear to have a specific geographic focus but provides comprehensive coverage of global trends within the healthcare and pharmaceutical industries. When reaching out to him with pitches or expert commentary offers it should align with these thematic areas for higher chances of engagement.

This information evolves through artificial intelligence and human feedback. Improve this profile .

Journalists With Similar Coverage:

Based on similarity of content.
Eric Sagonowsky

Eric Sagonowsky

Senior Editor
*********ky@**************com
Publications
Fierce Pharma, Biotech
Most recent topics
Not enough data
Kate Goodwin

Kate Goodwin

Life Sciences Writer
**********in@**********om
Publications
BioSpace, indesignlive.com
Most recent topics
Not enough data
Adam Feuerstein

Adam Feuerstein

Senior Writer, National Biotech Columnist
************ein@**********om
Publications
STAT, everand.com
Most recent topics
Not enough data
Ned Pagliarulo

Ned Pagliarulo

Lead Editor
*********lo@*************com
Publications
BioPharma Dive
Most recent topics
Not enough data
Lei Lei Wu

Lei Lei Wu

News Reporter
**u@**************com
Publications
Endpoints News
Most recent topics
Not enough data
Anna Bratulic

Anna Bratulic

Publications
firstwordpharma.com, firstwordhealthtech.com
Most recent topics
Not enough data

Articles

STAT

Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry

Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry

By: Jason Mast, Ed Silverman, Allison DeAngelis, Andrew Joseph, Matthew Herper

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them. Many said they'd take a wait-and-see approach, but others took a more definitive stance. “I'm optimistic,” Bausch + Lomb CEO Brent Saunders told STAT. Zach Weinberg, CEO of Curie.Bio, said that while Trump's policies on health care have been known to shift, “R.F.K. is scary and unqualified to lead anything but a trip to the supermarket.”

© 2024 Intelligent Relations